Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026

Sino Biopharmaceutical ( (HK:1177) ) has issued an announcement.

Sino Biopharmaceutical’s wholly owned unit LaNova Medicines has showcased new preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the American Association for Cancer Research Annual Meeting 2026, underscoring its push into next-generation oncology biologics. The programs target solid tumors with technologies aimed at improving tumor selectivity and safety profiles, reinforcing the group’s positioning in high-value cancer therapeutics.

LM-364, a Nectin-4 tumor microenvironment-activated ADC, demonstrated strong antitumor activity across multiple patient-derived xenograft models and a favorable safety profile in animal studies, and has already progressed to an IND filing with the U.S. FDA ahead of a planned first-in-human trial in 2026. LM-338, designed as a potential first-in-class ADC against the tumor-specific STn glycan antigen, showed high target specificity and efficient internalization, signaling future pipeline expansion in solid tumor indications if later-stage data confirm these preclinical results.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a China-focused pharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative therapies, with a strong emphasis on oncology. Through subsidiaries such as LaNova Medicines, it develops advanced antibody-drug conjugates and other targeted treatments for solid tumors and other cancers.

Average Trading Volume: 69,721,589

Technical Sentiment Signal: Buy

Current Market Cap: HK$110.3B

Learn more about 1177 stock on TipRanks’ Stock Analysis page.